Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
14.26
+0.77 (5.71%)
At close: Apr 13, 2026, 4:00 PM EDT
14.31
+0.05 (0.35%)
After-hours: Apr 13, 2026, 7:52 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 377 employees as of December 31, 2025. The number of employees decreased by 26 or -6.45% compared to the previous year.
Employees
377
Change (1Y)
-26
Growth (1Y)
-6.45%
Revenue / Employee
$179,499
Profits / Employee
-$1,094,679
Market Cap
1.68B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 377 | -26 | -6.45% |
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Vir Biotechnology | 367 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 298 |
| Harmony Biosciences Holdings | 293 |
| Viridian Therapeutics | 252 |
NTLA News
- 10 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial - Benzinga
- 6 weeks ago - US FDA lifts clinical hold on Intellia's heart disease gene therapy trial - Reuters
- 6 weeks ago - Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - GlobeNewsWire